Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business ...
Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, ...
Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ETCompany ParticipantsAndrew Guggenhime - President and ...
Vaxcyte, Inc.: Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and ...
Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and ...